notificationsアラート設定
~
検索条件をクリア

アブストラクト

Title がん免疫療法の現状と今後の展望
Subtitle Cancer-Immunological Topics
Authors 北野滋久
Authors (kana)
Organization がん研究会有明病院 先端医療開発センターがん免疫治療開発部 部長
Journal がん免疫療法
Volume 4
Number 1
Page 49-58
Year/Month 2020 / 5
Article 報告
Publisher メディカルレビュー社
Abstract 「はじめに」近年, 各種がんに免疫チェックポイント阻害剤(immune checkpoint inhibitor: ICI)の適応拡大が進んでいるが, 単剤での治療効果は限定的であり, 承認されているほとんどのがん種において奏効割合は15〜40%程度にとどまる. 治療効果の向上を目指すため, 現在, すでに承認されているICI(抗CTLA-4〔cytotoxic T-lymphocyte antigen-4〕抗体, 抗PD-1〔programmed cell death-1〕抗体, 抗PD-L1〔programmed cell death 1-ligand 1〕抗体)を軸として各種治療法との併用療法(複合がん免疫療法)の開発が進められている. 本稿では, ICIの開発状況と今後の展望について概説する. 「ICI単剤の開発状況」「抗CTLA-4抗体療法」1996年にAllison博士らによってマウスモデルにおいて抗CTLA-4抗体による抗腫瘍効果が報告され, がん免疫療法への臨床応用が検討されるようになった.
Practice 臨床医学：一般
Keywords
  • 全文ダウンロード： 従量制、基本料金制の方共に913円(税込) です。
download全文ダウンロード(11.60MB)

参考文献

  • 1) KLeach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade, Science. 1996;271:1734-6.
  • 2) Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206:1717-25.
  • 3) Simpson TR, Li F, Montalvo-Ortiz W, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013;210:1695-710.
    pubmed
  • 4) Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab:contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010;37:533-46.
    pubmed
  • 5) Lipson EJ, Drake CG. Ipilimumab:an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011;17:6958-62.
    pubmed
残りの32件を表示する
  • 6) Ribas A, Hanson DC, Noe DA, et al. Tremelimumab(CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist, 2007;12:873-83.
    pubmed
  • 7) Quezada SA, Simpson TR, Peggs KS, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207:637-50.
    pubmed
  • 8) Kitano S, Tsuji T, Liu C, et al. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res. 2013;1:235-44.
    pubmed
  • 9) Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4:336-47.
    pubmed
  • 10) Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682-7.
    pubmed
  • 11) Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015-29.
    pubmed
  • 12) Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467-77.
    pubmed
  • 13) Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207-12.
    pubmed
  • 14) Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27:111-22.
    pubmed
  • 15) Park JJ, Omiya R, Matsumura Y, et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood. 2010;116:1291-8.
    pubmed
  • 16) Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350-5.
    pubmed
  • 17) Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma:2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17:1558-68.
  • 18) Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006-17.
    pubmed
  • 19) Beatty GL, O'Dwyer PJ, Clark J, et al. First-in-human phase I study of the oral inhibitor of indoteamine 2,3-dioxygenase-1 epacadostat(INCB024360) in patients with advanced solid malignancies. Clin Cancer Res. 2017;23:3269-76.
  • 20) Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51-72.
    pubmed
  • 21) Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078-92.
    pubmed
  • 22) Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med, 2018;378:2288-301.
    pubmed
  • 23) Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379:2040-51.
    pubmed
  • 24) Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-9.
    pubmed
  • 25) Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nabpaclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108-21.
  • 26) Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies reinstating immunosurveillance. Immunity. 2013;39:74-88.
    pubmed
  • 27) Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy:harnessing potential synergies. Cancer Immunol Res. 2015;3:436-43.
    pubmed
  • 28) Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell. 2015;28:690-714.
    pubmed
  • 29) Voron T, Marcheteau E, Pernot S, et al. Control of the immune response by pro-angiogenic factors. Front Oncol. 2014;4:70.
    pubmed
  • 30) Wada J, Suzuki H, Fuchino R, et al. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res. 2009;29:881-8.
  • 31) Osada T, Chong G, Tansik R, et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother. 2008;57:1115-24.
  • 32) Manzoni M, Rovati B, Ronzoni M, et al. Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. Oncology. 2010;79:187-96.
    pubmed
  • 33) Shrimali RK, Yu Z, Theoret MR, et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70:6171-80.
    pubmed
  • 34) Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1103-15.
    pubmed
  • 35) Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116-27.
    pubmed
  • 36) Rodriguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol. 2018;39:644-55.
    pubmed
  • 37) Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925-31.
はじめての方へ
個人／法人会員登録のご案内